Palbociclib, when combined with MEK and OxPhos inhibitors, exhibited tumor-suppressing efficacy, and in another study, abemaciclib and a hepatocyte growth factor inhibitor synergistically inhibited tumor growth in xenografts. The gene discussed is MAP2K7; the disease is neoplasm.